Lapatinib plus capecitabine was compared to neratinib plus capecitabine in patients with metastatic HER2-positive BC, who had received at least two prior lines of therapy as part of the Phase 3 NALA trial in patients with metastatic HER2+ BC who had received at least two prior lines of therapy (Dai et al., 2021). Here, ERBB2 is linked to breast cancer.